Intervention
lenvatinib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownEfficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC PatientsNCT06028633 · 2023-10-01
NOT_YET_RECRUITINGStudy of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)NCT06036836 · 2023-09-29
COMPLETEDSafety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)NCT04938817 · 2021-08-19
ACTIVE_NOT_RECRUITINGStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)NCT04776148 · 2021-03-29
COMPLETEDEfficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)NCT03776136 · 2019-01-30
COMPLETEDSafety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)NCT03713593 · 2018-12-31
COMPLETEDPhase II Study of Single Agent LenvatinibNCT03168074 · 2017-03-28
UNKNOWNPhase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid TumorsNCT03006887 · 2017-01-12
COMPLETEDCommon conditions
Advanced Melanoma1Advanced Non-squamous Non-small-cell Lung Cancer1Breast Cancer1Carcinoma, Hepatocellular1Colorectal Neoplasms1Cutaneous Squamous Cell Carcinoma1Endometrial Cancer1Metastatic Non-squamous Non Small Cell Lung Cancer1Recurrent Non-Squamous Non-Small Cell Lung Cancer1Small Cell Lung Carcinoma1Solid Tumor1Solid Tumors1
Leading sponsors
Trial status mix
COMPLETED5
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
UNKNOWN1
Phase mix
PHASE25
PHASE12
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.